Cidara Therapeutics, Inc. (NASDAQ:CDTX) Director Timothy R. Franson bought 7,000 shares of the business’s stock in a transaction on Monday, September 13th. The stock was purchased at an average price of $2.12 per share, for a total transaction of $14,840.00. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.
NASDAQ:CDTX opened at $2.02 on Wednesday. Cidara Therapeutics, Inc. has a twelve month low of $1.46 and a twelve month high of $3.40. The firm has a market capitalization of $100.00 million, a price-to-earnings ratio of -1.82 and a beta of 1.36. The stock’s 50 day moving average price is $1.83 and its two-hundred day moving average price is $2.07.
Cidara Therapeutics (NASDAQ:CDTX) last issued its earnings results on Thursday, August 12th. The biotechnology company reported $0.18 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.40. Cidara Therapeutics had a negative net margin of 117.68% and a negative return on equity of 336.43%. As a group, equities research analysts forecast that Cidara Therapeutics, Inc. will post -1.03 EPS for the current year.
Separately, Zacks Investment Research upgraded Cidara Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 4th.
About Cidara Therapeutics
Cidara Therapeutics, Inc is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.
Further Reading: Bollinger Bands
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.